 |
|
|
|
|
|
|
|
 |
 |
|
|
|
 |
|
|
|
|
|
"We are a clinical-stage biotechnology company focused on the development and partnering of targeted treatments for cancer and infectious diseases. Our lead cancer product candidate, Telomelysin® (OBP-301), is a first-in-class product utilizing oncolytic adenovirus technology that replicates and spreads within solid tumors, causing the death of cancer cells without harming healthy cells, and not causing severe adverse effects normally seen with existing traditional cancer therapies. Our lead antiviral product candidate FESTINAVIR®(OBP-601) is a novel NRTI for HIV/AIDS therapy. FESTINAVIR® has highly promising safety and resistance profiles. We work towards accelerating development through collaborations with leading institutions and the science community. Our strategic focus is to maximize and realize the potential of our products through partnering." |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Copyright
(c)2004-2005, Oncolys BioPharma Inc. All rights reserved.
|
|
